increased risk of extrapyramidal symptoms associated with all high-potency neuroleptics
Stelazine advertisement, 1990
American Journal of Psychiatry, Vol. 147, No. 1.

Emerging from the Darkness of Schizophrenia
Stelazine® brand of trifluoperazine HCl
~ Controls psychotic symptoms   ~ "Activates" the withdrawn patient   ~ Avoids excessive sedation
~ Reduces the risk of side effects*   ~ Encourages adherence with b.i.d. dosing
*With 'Stelazine', the risk of anticholinergic effects and hypotension is relatively low. 'Stelazine' shares the increased risk of
extrapyramidal symptoms associated with all high-potency neuroleptics; when they occur, these can generally be readily controlled.
Adverse reactions: Drowsiness, dizziness, skin reactions, rash, dry mouth, insomnia, amenorrhea, fatigue, muscular weakness,
anorexia, lactation, blurred vision.   Neuromuscular (extrapyramidal) reactions: motor restlessness, dystonias, pseudo-parkinsonism,
tardive dyskinesia, and a variant, tardive dystonia.   NOTE: Sudden death in patients taking phenothiazines (apparently due to
cardiac arrest or asphyxia due to failure of cough reflex) has been reported.           © SK&F Lab Co., 1989

Back to Marvelous Mental Medicine Stelazine straitjacket


© 2008 Bonkers Institute for Nearly Genuine Research